Finally, the combination of mWTX-613 treatment with various checkpoint inhibitor molecules resulted in improved anti-tumor efficacy in syngeneic models. Together, these data support the advancement of this innovative IFNα therapy into clinical testing.
over 1 year ago
Combination therapy • Checkpoint inhibition
|
CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1)
The WTX-330 INDUKINE™ molecule, a wild-type IL-12 pro-drug, contains a half-life extension (HLE) domain to support infrequent dosing and a high affinity anti-IL-12 neutralizing antibody domain to maintain the molecule in its inactive state in the periphery. Similar studies for WTX-613 are on-going. Preclinical data obtained so far for both programs support the continued development and future evaluation of these innovative and differentiated therapies in hematologic malignancies, both as monotherapies and in multiple combinations with standard of care.
3 years ago
Preclinical
|
CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
Specifically, the WTX-613 surrogate was better than native IFNα1 in inducing CD8+, NK, and DC cells. Conclusions Preclinical data obtained so far support the continued development of this innovative and differentiated engineered IFNα therapy and progression into clinical trials.
3 years ago
Preclinical
|
CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)